Catalyst Pharmaceuticals, Inc. (CPRX) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript

Catalyst Pharmaceuticals, Inc. (CPRX) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript

Seeking Alpha • Dec 8, 2025

Catalyst (CPRX) Up 10% Since Last Earnings Report: Can It Continue?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 5, 2025

Catalyst Pharmaceutical (CPRX) Recently Broke Out Above the 20-Day Moving Average

From a technical perspective, Catalyst Pharmaceutical (CPRX) is looking like an interesting pick, as it just reached a key level of support. CPRX recently overtook the 20-day moving average, and this suggests a short-term bullish trend.

Zacks Investment Research • Dec 4, 2025

Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seeking Alpha • Dec 2, 2025

Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Dec 2, 2025

Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Dec 1, 2025

Wall Street Analysts Think Catalyst (CPRX) Could Surge 47.37%: Read This Before Placing a Bet

The mean of analysts' price targets for Catalyst (CPRX) points to a 47.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Dec 1, 2025

CPRX or DSNKY: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).

Zacks Investment Research • Dec 1, 2025

Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in the Bank of America CNS Therapeutics Virtual Conference on Monday, December 8, 2025.

GlobeNewsWire • Nov 24, 2025

Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™

Attributes 249% Revenue Growth to Portfolio Momentum and Focused Execution Attributes 249% Revenue Growth to Portfolio Momentum and Focused Execution

GlobeNewsWire • Nov 19, 2025